Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Daxor Corp (DXR)

Daxor Corp (DXR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 33,133
  • Shares Outstanding, K 3,747
  • Annual Sales, $ 1,450 K
  • Annual Income, $ -7,190 K
  • 60-Month Beta -0.51
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr N/A
See More
  • Average Estimate N/A
  • Number of Estimates N/A
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.86 +12.50%
on 07/24/19
10.49 -15.70%
on 07/30/19
+0.97 (+12.36%)
since 07/15/19
3-Month
7.13 +24.00%
on 06/26/19
10.49 -15.70%
on 07/30/19
-0.61 (-6.43%)
since 05/16/19
52-Week
4.30 +105.65%
on 08/17/18
19.95 -55.68%
on 02/26/19
+3.60 (+68.76%)
since 08/16/18

Most Recent Stories

More News
Daxor Corporation Announces the Acquisition of the BVA-100(R) Blood Volume Analyzer by a Leading Academic Health Center in the Pacific Northwest

Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announces the acquisition of Daxor's...

DXR : 8.84 (unch)
Daxor Corporation to Exhibit at the Society of Hospital Medicine (SHM) Annual Conference 2019

Daxor Corporation (NYSE MKT: DXR) an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement today announces it will be exhibiting at...

DXR : 8.84 (unch)
Daxor Corporation Addresses and Corrects Erroneous Seeking Alpha Healthcare News Editor Article of March 20, 2019

Author incorrectly claimed, "The company's sole product is a blood volume analyzer called the BVA-100 but there does not appear to be any sales to date."

DXR : 8.84 (unch)
Daxor Corporation to Present at the 31st Annual Roth Conference on March 19, 2019

Daxor Corporation (NYSE MKT: DXR) an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announced that Michael Feldschuh,...

DXR : 8.84 (unch)
Daxor Corporation Announces Rise in Kit Sales and Files Form N-CSR For 2018

Daxor Corporation (NYSE MKT: DXR) an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement today filed a Form N-CSR disclosing its...

CHFS : 2.44 (-2.01%)
DXR : 8.84 (unch)
New Research Further Demonstrates Clinical Utility and Improved Ease of Use with Daxor Corporation's Blood Volume Analyzer (BVA-100(R)) in Critical Care

Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announces new research from the...

DXR : 8.84 (unch)
Daxor Corporation to Exhibit at the Society for Critical Care Medicine 48th Congress

New Research Abstracts Scheduled for Presentation on Daxor's BVA-100

DXR : 8.84 (unch)
Daxor Corporation Appoints Guido Manzo, Vice President of Sales

Daxor Corporation (NYSE MKT: DXR), an innovative medical instrumentation and biotechnology company focused on blood volume measurement today announces the appointment of Guido Manzo as Vice President of...

DXR : 8.84 (unch)
Daxor Corporation Announces Acquisition of BVA-100(R) Blood Volume Analyzer to Aspirus Wausau Hospital in Wisconsin

Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announces that Aspirus Wausau Hospital...

DXR : 8.84 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More Share

Trade DXR with:

Business Summary

Daxor Corporation is a medical device manufacturing corporation with additional biotech services.

See More

Key Turning Points

2nd Resistance Point 8.84
1st Resistance Point 8.84
Last Price 8.84
1st Support Level 8.84
2nd Support Level 8.84

See More

52-Week High 19.95
Fibonacci 61.8% 13.97
Fibonacci 50% 12.13
Fibonacci 38.2% 10.28
Last Price 8.84
52-Week Low 4.30

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar